Alert: Because flu cases are on the rise, children 12 and younger will be restricted from visiting hospitals and certain inpatient facilities. Learn more.

Research and Clinical Trials

BMS CA209498: A Randomized Phase 3 Open Label Study of Nivolumab vs Temozolomide Each in Combination with Radiation Therapy in Newly Diagnosed Adult Subjects with Unmethylated MGMT (tumor O-6-methylguanine DNA methyltransferase) Glioblastoma
Brief Description  
Primary: To compare overall survival (OS) of nivolumab plus radiation therapy (RT + Nivolumab) vs temazolomide plus radiation therapy (RT+ TMZ) in subjects with newly-diagnosed GBM and unmethylated MGMT tumors after surgical resection. Secondary: Compare investigator assessed progression-free survival (PFS) of RT + nibolumab vs RT + TMZ. To estimate overall survival rate at 24 months (OS [24] of RT + nivolumab vs RT + TMZ.
Who may be Eligible  
Please contact us for eligibility criteria.
Brain and Nervous System
Start Date  
IRB Number  
Principal Investigator  
Sumrall, Ashley Love
Contact Name  
Sylvia Rushing

For More Information, Contact  Sylvia  , Rushing
Phone:  980-442-2358 Fax:    
Email:  Sylvia.Rushing@carolinashealthcare.org
Address:1021 Morehead Medical Drive Suite 2200 Charlotte, 28204